Article info
PDFReviews
The pharmacological treatment of acquired nystagmus
- Correspondence to Christopher Kennard, Nuffield Department of Clinical Neurosciences, Oxford University Hospitals NHS Trust, Level 6, West Wing, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, UK; chris.kennard{at}ndcn.ox.ac.uk
Citation
The pharmacological treatment of acquired nystagmus
Publication history
- First published June 1, 2012.
Online issue publication
April 14, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Other content recommended for you
- Drug treatments for eye movement disorders
- Neuro-ophthalmology
- Gaze fixation deficits and their implication in ataxia–telangiectasia
- Diplopia and eye movement disorders
- Pontine lesions mimicking acute peripheral vestibulopathy
- The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study
- 4-aminopyridine restores visual ocular motor function in upbeat nystagmus
- Gabapentin but not vigabatrin is effective in the treatment of acquired nystagmus in multiple sclerosis: how valid is the GABAergic hypothesis?
- Upbeat nystagmus: clinicoanatomical correlation
- Use of HINTS in the acute vestibular syndrome. An Overview